Wegovy Health Issues: Weighing the Risks Against the Benefits

The side effects most likely to affect your day-to-day life

The health issues people most often experience on Wegovy are gastrointestinal, and they follow a recognisable pattern. Nausea tends to arrive first, often within a day or two of an injection, and can be accompanied by vomiting, loose stools, constipation, burping, or a general feeling of fullness that makes eating feel like a chore. Indigestion and reflux are also reported, and fatigue or mild headaches can crop up alongside them.

Timing is important here. These effects are typically at their worst after starting treatment or after each dose increase, because the body's response to the medicine changes at higher exposures. For most people, things settle within one to two weeks. For some, they persist at a lower level throughout. A practical checking habit worth building: keep a brief weekly note (even just a voice memo) of how your digestion felt in the first 48 hours after each injection. It takes under a minute and gives you genuinely useful information to share with your prescriber at review.

Injection-site reactions (redness, itching or a small lump) are another commonly reported issue, and rotating the injection site (abdomen, thigh or upper arm) reduces their likelihood. The NHS medicines page for semaglutide lists the full side-effect profile with frequency data and is worth bookmarking for reference.

Serious health risks: rare, but worth understanding clearly

The more serious health concerns associated with Wegovy are uncommon, but they are real and the MHRA takes them seriously. Acute pancreatitis (inflammation of the pancreas) was the subject of a formal Drug Safety Update published in January 2026, covering GLP-1 medicines as a class. The signal is infrequent, but the consequences can be severe. The symptom to act on immediately is a severe, persistent pain in the upper abdomen that spreads to the back, with or without vomiting. That is a 999-or-A&E situation, not a wait-and-see one.

Gallbladder problems are also reported at higher rates in people on GLP-1 treatments, gallstones and gallbladder inflammation included. Symptoms such as sharp upper-right abdominal pain, especially after eating, are worth reporting to your GP or prescriber promptly rather than attributing to general GI upset.

Severe nausea or vomiting that prevents adequate fluid intake can lead to dehydration and, in turn, strain on the kidneys. Anyone who cannot keep fluids down for more than a day should seek medical advice. People with a history of pancreatitis, or certain gastrointestinal conditions, should discuss these specifically with their prescriber before starting. A full overview of semaglutide's safety evidence is available through NICE technology appraisal TA875, which underpins the NHS recommendation for Wegovy.

Health issues that often go less discussed: mood and mental wellbeing

Alongside the physical side effects, there is a growing body of clinical interest in how Wegovy affects mood, motivation and mental health. Some people report improved wellbeing as their weight changes and the pressure on their joints, sleep and energy reduces. Others notice something less straightforward: shifts in how food feels emotionally, or a flatness in mood that they connect to the treatment.

The MHRA and NHS advise that anyone on a GLP-1 medicine who notices low mood, withdrawal from daily life, or thoughts of self-harm should contact their prescriber or GP without delay. This is not a reason to avoid treatment for most people, but it is a reason to ensure your prescriber knows your mental health history before you start. Our guide to Wegovy and mental health explores this question in more detail, drawing on the current evidence and what it means in practice.

For a fuller picture of the positive side, the documented cardiovascular and metabolic effects of sustained weight loss matter too, the health benefits of Wegovy covers that evidence separately.

Who should approach Wegovy's health profile with extra caution

For most adults who meet the licensed criteria (a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea) Wegovy's health risks sit in a context of significant, well-evidenced clinical benefit. But certain groups warrant particular care.

Pregnancy, breastfeeding and actively trying to conceive are all situations in which Wegovy is not recommended. The MHRA advises effective contraception throughout treatment; women using the oral contraceptive pill should be aware that, while reduced absorption has not been established for semaglutide in the same way as tirzepatide, a prescriber should be consulted about contraceptive choices. The medicine is not licensed for anyone under 18.

People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use semaglutide. Prior pancreatitis, serious kidney disease or gastroparesis are also conditions that need careful prescriber review before any GLP-1 medicine is considered. A general overview of what the treatment involves is available on our Wegovy information page. For context on how broader semaglutide concerns are categorised, our look at semaglutide issues covers the wider class picture.

If you are thinking through whether Wegovy is a healthy choice for your circumstances, the right next step is a clinical conversation. At nume, a GPhC-registered Independent Prescriber (not an automated system) reviews every consultation. Check your eligibility and start your free consultation to get a considered clinical view of whether Wegovy is suitable for you, and you can also read about the issues with Wegovy that come up most often in practice before you do.